Case Report Complete Remission with Loncastuximab Tesirine In An Elderly Patient with Relapsed/Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type
by Martina Cantelli1*, Giovanni Marconi 2, Monica Tani1, Arbana Dizdari1, Marzia Salvucci1, Francesco Lanza2
1Hematology Unit and Romagna Transplant Network, Hospital of Ravenna, Ravenna, Italy
2Hematology Unit and Romagna Transplant Network, Hospital of Ravenna, University of Bologna, Ravenna, Italy
*Corresponding author: Martina Cantelli, Hematology Unit and Romagna Transplant Network, Hospital of Ravenna, Ravenna, Italy.
Received Date: 24 August 2025
Accepted Date: 28 August 2025
Published Date: 01 September 2025
Citation: Cantelli M, Marconi G, Tani M, Dizdari A, Salvucci M, et al. (2025). Complete Remission with Loncastuximab Tesirine In An Elderly Patient with Relapsed/Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. Ann Case Report. 10: 2393. https://doi.org/10.29011/2574-7754.102393
Introduction
Primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) is a rare but aggressive lymphoma, recognized as a distinct clinicopathological entity in the 2022 World Health Organization (WHO) classification. [1] It accounts for approximately 4% of newly diagnosed primary cutaneous lymphomas annually and 20% of primary cutaneous B-cell lymphomas [2].
PCDLBCL-LT typically affects elderly individuals, with a median age at diagnosis of 70 years, and exhibits a significant female predominance (male-to-female ratio of 1: 3-4). [3] Clinically, it commonly presents as rapidly growing red-brown to violaceous nodules or tumours, primarily located on the legs and often accompanied by ulceration. Only 10-15% of patients present with tumour lesions outside the legs [3,4].
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.